SUMMARY Newborn screening for cystic fibrosis (CF) by dried blood spot immunoreactive trypsin (IRT) assay is now feasible, but the benefits are disputed. We have studied the symptoms and signs at diagnosis in 48 babies detected during a newborn screening programme, and also the delay between presentation with symptoms and diagnosis in all 33 babies diagnosed at our CF clinic in the two years before screening began. Eleven of the 48 screened babies had meconium ileus, 16 had gastrointestinal symptoms only, and 14 had both respiratory and gastrointestinal symptoms at the time of diagnosis. Five of the remaining 7 babies developed clear cut symptoms or signs soon after diagnosis. Thus, 96 % (46 of 48) of the babies had symptoms by 3 months of age. Of the 33 infants diagnosed clinically in the two years immediately before screening, 13 (39%) were over 12 months of age at diagnosis. Moreover, the mean delay between presentation with symptoms and diagnosis of CF in these infants was 2' 6 years. Our data show that the delay between onset of symptoms and diagnosis is far greater than previously supposed and that most babies detected by our screening programme already had symptoms that warranted treatment at the time of their diagnosis.
While it has been taken for granted that the earlier a child with symptoms of cystic fibrosis (CF) is treated the better the prognosis,' 2 there is no agreement on whether very early diagnosis by newborn screening followed by prophylactic treatment confers any extra benefit.34 Early diagnosis by screening would obviously facilitate prompt, aggressive treatment of respiratory or gastrointestinal symptoms, or both, as soon as they arise. The delay between the onset of symptoms and clinical diagnosis of CF has been examined in 33 new patients presenting at a large CF clinic during 1980 and 1981. The natural history of the disorder during the first weeks of life has also been studied in 48 patients diagnosed by newborn screening in 1981-3.
Patients and methods
Patients diagnosed clinically in the two years before newborn screening started. All 33 patients with CF diagnosed at this hospital in the two years before neonatal screening was started were included. The parents of the children were interviewed on one or more occasions by one of us (SJT Eleven of the 48 babies presented in the neonatal period with meconium ileus. Thirty of the remaining 37 had gastrointestinal symptoms at the time of diagnosis. These symptoms ranged from severe failure to thrive, with weight loss and oedema to increased diarrhoea, with fat globules in the stools. Fourteen of these 30 babies also had pulmonary symptoms, although these were mild in 7. One baby with no pulmonary symptoms had an abnormal chest radiograph with right upper lobe collapse. No baby had pulmonary symptoms alone at this time. Only 7 babies had no symptoms at diagnosis, but four of these developed symptomsbronchitis in one, and a fall off in weight gain in three-soon afterwards. A fifth asymptomatic baby, upon his first visit to the clinic at two months, had Staphylococcus aureus and Pseudomonas aeruginosa cultured from a pharyngeal aspirate. (Table 3) Among those 30 babies with symptoms, the diagnosis of CF was only being considered in four, three of whom had siblings with known CF. During the period of screening in New South Wales, it is likely that most of the cases were identified and only one child is known to have been missed by the screen. The incidence of CF detected during this period was 1/2400, which is close to the expected incidence.10 At the time of diagnosis, 85 % of the screened babies already had symptoms or signs of CF, and by 3 months of age this figure was 96%. These findings indicate that the usual delay between onset of symptoms and diagnosis is far greater than that suggested by retrospective enquiry. Now that screening for CF is feasible, with acceptably low false positive and false negative rates,6 it is important that controlled studies be undertaken to investigate its value. In the meantime, our study has important implications for screeningparticularly in light of the high incidence of CF symptoms at such an early age. It is not clear at present when to start treatment of CF. Nevertheless, once there are respiratory or gastrointestinal symptoms, or signs of the disease, appropriate treatment must be offered. Our investigation shows that without screening there are appreciable delays between onset of symptoms and diagnosis. The data from the group of screened babies suggest that these delays are far more substantial than previously suspected; almost all babies had symptoms at 3 months. Hence, screening for CF may be justified not only in relation to prophylactic treatment, the benefit of which is disputed, but also to facilitate early and aggressive treatment of mild symptoms, which is not at present being achieved. 
Discussion
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Haemolysis occurs constantly in intra-and extrauterine life but normally is kept within bounds by some mechanism. Hampson has suggested that haemolysis may be controlled in intrauterine life by something produced by the mother and passed on by her to the fetus, which in extrauterine life is elaborated by the infant itself; for at birth a considerable degree of haemolysis occurs owing to alterations in the oxygen tension of its surroundings, which is prevented from becoming excessive by the anti-haemolytic agent. If this factor is absent or insufficient, excessive haemolysis with the production of anaemia and perhaps severe jaundice may occur; this may however, be prevented if the anti-haemolytic factor is given by administration of blood serum. This is the basis of the treatment of icterus gravis by injections of blood serum, a treatment which we owe to Hampson and which has proved a great success . .. Such an hypothesis would furnish an adequate explanation for the fact that jaundice is more frequent and severe in preterm than term children; also of the development of haemolytic anaemia in the preterm and of its prevention by blood transfusion . . . It . . . fails adequately to explain hydrops fetalis and those cases of icterus gravis which develop spastic diplegia in later life and those which show necrotic changes in the liver. 
